within Pharmacolibrary.Drugs.ATC.C;

model C09CA06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 6.166666666666666e-06,
    adminDuration  = 600,
    adminMass      = 16 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.033,
    k12             = 0.9,
    k21             = 0.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09CA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Candesartan is an angiotensin II receptor blocker (ARB) used primarily for the treatment of hypertension and heart failure. It is an approved drug and widely prescribed for blood pressure control and prevention of cardiovascular events.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, single oral dose administration.</p><h4>References</h4><ol><li><p>Gleiter, CH, &amp; Mörike, KE (2002). Clinical pharmacokinetics of candesartan. <i>Clinical pharmacokinetics</i> 41(1) 7–17. DOI:<a href=\"https://doi.org/10.2165/00003088-200241010-00002\">10.2165/00003088-200241010-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11825094/\">https://pubmed.ncbi.nlm.nih.gov/11825094</a></p></li><li><p>Kassem, I, et al., &amp; de Denus, S (2021). Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. <i>Clinical and translational science</i> 14(1) 194–203. DOI:<a href=\"https://doi.org/10.1111/cts.12842\">10.1111/cts.12842</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32702160/\">https://pubmed.ncbi.nlm.nih.gov/32702160</a></p></li><li><p>Dudhipala, N, &amp; Veerabrahma, K (2017). Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability. <i>Therapeutic delivery</i> 8(2) 79–88. DOI:<a href=\"https://doi.org/10.4155/tde-2016-0063\">10.4155/tde-2016-0063</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28088883/\">https://pubmed.ncbi.nlm.nih.gov/28088883</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09CA06;
